IL6 and congenital rubella syndrome: Ruxolitinib, formerly known as INCB018424 or INC424, an inhibitor of the IL6/JAK/STAT3 signaling pathway, is effective in mitigating CRS by inhibiting the activation of T cells and CAR-T cells and down-regulating the expression of related cytokines, thereby inhibiting the activation of cytokine receptors (50).